Global X Japan Co. Ltd. purchased a new stake in Astera Labs, Inc. (NASDAQ:ALAB - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor purchased 9,328 shares of the company's stock, valued at approximately $1,552,000.
Other institutional investors have also recently made changes to their positions in the company. Clearstead Advisors LLC lifted its holdings in Astera Labs by 13.6% in the third quarter. Clearstead Advisors LLC now owns 636 shares of the company's stock valued at $125,000 after acquiring an additional 76 shares during the last quarter. Great Valley Advisor Group Inc. increased its position in shares of Astera Labs by 2.2% during the 2nd quarter. Great Valley Advisor Group Inc. now owns 4,119 shares of the company's stock worth $372,000 after purchasing an additional 90 shares during the last quarter. Rye Brook Capital LLC boosted its stake in Astera Labs by 1.1% during the third quarter. Rye Brook Capital LLC now owns 9,200 shares of the company's stock worth $1,801,000 after buying an additional 100 shares during the period. Hilltop National Bank raised its stake in shares of Astera Labs by 100.0% in the 4th quarter. Hilltop National Bank now owns 200 shares of the company's stock valued at $33,000 after acquiring an additional 100 shares during the period. Finally, Assetmark Inc. lifted its holdings in shares of Astera Labs by 374.1% in the 3rd quarter. Assetmark Inc. now owns 128 shares of the company's stock worth $25,000 after acquiring an additional 101 shares during the last quarter. Hedge funds and other institutional investors own 60.47% of the company's stock.
Insider Transactions at Astera Labs
In other news, CFO Michael Truett Tate sold 12,001 shares of the firm's stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $123.81, for a total value of $1,485,843.81. Following the sale, the chief financial officer directly owned 192,083 shares in the company, valued at approximately $23,781,796.23. This trade represents a 5.88% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, General Counsel Philip Mazzara sold 10,000 shares of Astera Labs stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $117.47, for a total transaction of $1,174,700.00. Following the sale, the general counsel directly owned 128,084 shares of the company's stock, valued at approximately $15,046,027.48. This trade represents a 7.24% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 384,292 shares of company stock valued at $48,724,919 over the last quarter. Insiders own 12.50% of the company's stock.
Astera Labs Stock Down 5.6%
NASDAQ:ALAB opened at $113.61 on Friday. Astera Labs, Inc. has a 52 week low of $47.13 and a 52 week high of $262.90. The company has a fifty day simple moving average of $139.69 and a two-hundred day simple moving average of $164.44. The company has a market cap of $19.46 billion, a price-to-earnings ratio of 93.12, a price-to-earnings-growth ratio of 2.37 and a beta of 1.74.
Astera Labs (NASDAQ:ALAB - Get Free Report) last released its earnings results on Tuesday, February 10th. The company reported $0.58 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.51 by $0.07. The firm had revenue of $270.58 million during the quarter, compared to analyst estimates of $249.46 million. Astera Labs had a return on equity of 16.12% and a net margin of 25.70%.Astera Labs's revenue was up 91.8% compared to the same quarter last year. During the same period last year, the business posted $0.37 earnings per share. Astera Labs has set its Q1 2026 guidance at 0.530-0.540 EPS. On average, analysts expect that Astera Labs, Inc. will post 0.34 EPS for the current year.
Analyst Ratings Changes
ALAB has been the subject of a number of research analyst reports. Weiss Ratings cut shares of Astera Labs from a "hold (c-)" rating to a "sell (d+)" rating in a research report on Monday, February 23rd. Loop Capital assumed coverage on Astera Labs in a research note on Thursday, March 5th. They set a "buy" rating and a $250.00 price target on the stock. Morgan Stanley reaffirmed an "overweight" rating and issued a $210.00 price objective on shares of Astera Labs in a research note on Wednesday, December 3rd. Barclays set a $165.00 target price on Astera Labs in a research note on Thursday, January 15th. Finally, Royal Bank Of Canada began coverage on Astera Labs in a research report on Wednesday, January 14th. They issued an "outperform" rating and a $225.00 target price for the company. Fifteen equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $202.22.
Check Out Our Latest Stock Report on ALAB
Astera Labs Company Profile
(
Free Report)
Astera Labs is a fabless semiconductor company that develops connectivity solutions for data center and cloud infrastructure. The firm focuses on addressing signal integrity and link management challenges that arise as server architectures incorporate higher-bandwidth processors and accelerators. Its technology is aimed at improving reliability and performance for high-speed interconnects used in servers, storage systems and compute accelerators.
The company's product portfolio centers on silicon devices and accompanying firmware and software that enhance and manage high-speed links.
Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Astera Labs, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Astera Labs wasn't on the list.
While Astera Labs currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.